
USFDA14 Nov 2026, 09:12 pm
Alembic Pharma gets USFDA nod for Binimetinib Tablets
AI Summary
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Binimetinib Tablets, in 15 mg and 45 mg strengths. This approval makes Alembic eligible for 180 days of generic drug exclusivity. Binimetinib, in combination with encorafenib, is used to treat specific types of melanoma and non-small cell lung cancer. The estimated market size for Binimetinib tablets is US$ 282 million. This marks Alembic's 230th final ANDA approval from the USFDA, adding to its total of 248 approvals.
Key Highlights
- USFDA final approval received for Binimetinib Tablets (15mg & 45mg).
- Eligible for 180 days of generic drug exclusivity.
- Therapeutically equivalent to Mektovi Tablets.
- Treats specific types of melanoma and NSCLC.
- Estimated market size of US$ 282 million.
Price Impact
More from APLLTD